The popular oral contraceptives Yaz and Yasmin have been tainted
recently by safety concerns raised by researchers, health advocates and
lawyers for plaintiffs who have filed lawsuits against manufacturer
Bayer Healthcare, the New York Times reports. These groups argue that the drugs put women at higher risk for strokes,
blood clots and other health problems than some other oral
contraceptives. Citing warning letters FDA sent to the company,
plaintiffs' attorneys contend that Bayer was aware or should have been
aware of the problems. These new concerns could "rattle consumer
confidence" and harm the drugs' image as the "go-to brands for women
under 35," according to some industry analysts, the Times reports.
In 2001, FDA approved Yasmin, which contains drospirenone, a
progestin that can increase the body's potassium levels. According to
the drug's label, the potassium increase may put women with liver and
kidney problems at higher risk for serious health problems. Yaz, which
also contains drospirenone and a lower dose of estrogen, was approved in
2006 as both a contraceptive and a treatment for premenstrual dysphoric
disorder and moderate acne.
The drugs' popularity is due in part to multimillion-dollar advertising
campaigns, and together Yasmin and Yaz brought in about $1.8 billion in
worldwide sales in 2008 for Bayer.
FDA in October 2008 sent Bayer a warning letter for running two false and misleading TV ads about Yaz. FDA said the ads overstated Yaz's efficacy, promoted it for conditions -- like premenstrual syndrome -- for which it is not approved, and downplayed serious risks associated with the drug. Bayer agreed in February 2009 to spend $20 million on a corrective ad campaign to address the misimpressions from the original campaign.
FDA sent another warning letter to Bayer in August 2009, this time regarding deviations from quality control standards at a manufacturing plant in Germany that makes drospirenone and other hormone ingredients used in the pills sold in the U.S. The letter said methods used by the facility to calculate variability in ingredients did not meet U.S. standards.
According to Bayer, the company has been served with 74 lawsuits brought by women who say they developed health problems after taking Yasmin or Yaz. According to the Times, because the drugs' labels warn of the risk of blood clots and stroke, the plaintiffs could have difficulty winning on the argument that Bayer should have issued stronger warnings. The plaintiffs might be more likely to prevail if lawyers are permitted to use the FDA warning letters to argue that misleading advertisements enticed women to take the pills, exposing them to health risks that they might not have otherwise encountered, the Times reports. Michael Santoro, an associate professor at Rutgers Business School who has studied ethics in the drug industry, said past warnings from FDA about advertising and quality control raise questions about Bayer's approach to complying with government guidelines.
An FDA spokesperson said the agency is reviewing the safety of oral contraceptives through a study designed to identify the incidence of blood clots, stroke and death among users of Yasmin and other oral contraceptives. Meanwhile, officials with Bayer said the company plans to vigorously defend itself against the lawsuits. Bayer also is conducting a postmarket study comparing Yaz's safety with that of other oral contraceptives (Singer, New York Times, 9/26).
Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women's Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women's Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company.
FDA in October 2008 sent Bayer a warning letter for running two false and misleading TV ads about Yaz. FDA said the ads overstated Yaz's efficacy, promoted it for conditions -- like premenstrual syndrome -- for which it is not approved, and downplayed serious risks associated with the drug. Bayer agreed in February 2009 to spend $20 million on a corrective ad campaign to address the misimpressions from the original campaign.
FDA sent another warning letter to Bayer in August 2009, this time regarding deviations from quality control standards at a manufacturing plant in Germany that makes drospirenone and other hormone ingredients used in the pills sold in the U.S. The letter said methods used by the facility to calculate variability in ingredients did not meet U.S. standards.
According to Bayer, the company has been served with 74 lawsuits brought by women who say they developed health problems after taking Yasmin or Yaz. According to the Times, because the drugs' labels warn of the risk of blood clots and stroke, the plaintiffs could have difficulty winning on the argument that Bayer should have issued stronger warnings. The plaintiffs might be more likely to prevail if lawyers are permitted to use the FDA warning letters to argue that misleading advertisements enticed women to take the pills, exposing them to health risks that they might not have otherwise encountered, the Times reports. Michael Santoro, an associate professor at Rutgers Business School who has studied ethics in the drug industry, said past warnings from FDA about advertising and quality control raise questions about Bayer's approach to complying with government guidelines.
An FDA spokesperson said the agency is reviewing the safety of oral contraceptives through a study designed to identify the incidence of blood clots, stroke and death among users of Yasmin and other oral contraceptives. Meanwhile, officials with Bayer said the company plans to vigorously defend itself against the lawsuits. Bayer also is conducting a postmarket study comparing Yaz's safety with that of other oral contraceptives (Singer, New York Times, 9/26).
Reprinted with kind permission from http://www.nationalpartnership.org. You can view the entire Daily Women's Health Policy Report, search the archives, or sign up for email delivery here. The Daily Women's Health Policy Report is a free service of the National Partnership for Women & Families, published by The Advisory Board Company.
1 comment:
Yes! Finally someone writes about parkette restaurant queen street west.
Visit my website at parquet justice définition
Post a Comment